Literature DB >> 27234497

Anti-inflammatory effects of sodium alginate/gelatine porous scaffolds merged with fucoidan in murine microglial BV2 cells.

Van-Tinh Nguyen1, Seok-Chun Ko1, Gun-Woo Oh1, Seong-Yeong Heo1, You-Jin Jeon2, Won Sun Park3, Il-Whan Choi4, Sung-Wook Choi5, Won-Kyo Jung6.   

Abstract

Microglia are the immune cells of the central nervous system (CNS). Overexpression of inflammatory mediators by microglia can induce several neurological diseases. Thus, the underlying basic requirement for neural tissue engineering is to develop materials that exhibit little or no neuro-inflammatory effects. In this study, we have developed a method to create porous scaffolds by adding fucoidan (Fu) into porous sodium alginate (Sa)/gelatine (G) (SaGFu). For mechanical characterization, in vitro degradation, stress/strain, swelling, and pore size were measured. Furthermore, the biocompatibility was evaluated by assessing the adhesion and proliferation of BV2 microglial cells on the SaGFu porous scaffolds using scanning electron microscopy (SEM) and lactate dehydrogenase (LDH) assay, respectively. Moreover, we studied the neuro-inflammatory effects of SaGFu on BV2 microglial cells. The effect of gelatine and fucoidan content on the various properties of the scaffold was investigated and the results showed that mechanical properties increased porosity and swelling ratio with an increase in the gelatine and fucoidan, while the in vitro biodegradability decreased. The average SaGFu diameter attained by fabrication of SaGFu ranged from 60 to 120μm with high porosity (74.44%-88.30%). Cell culture using gelatine 2.0% (SaG2Fu) and 4.0% (SaG4Fu), showed good cell proliferation; more than 60-80% that with Sa alone. Following stimulation with 0.5μg/mL LPS, microglia cultured in porous SaGFu decreased their expression of nitric oxide (NO), prostaglandin E2 (PGE2), and reactive oxygen species (ROS). SaG2Fu and SaG4Fu also inhibited the activation and translocation of p65 NF-κB protein levels, resulting in reduction of NO, ROS, and PGE2 production. These results provide insights into the diverse biological effects and opens new avenues for the applications of SaGFu in neuroscience.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biocompatibility; Fish skin gelatine; Fucoidan; Microglia; Neuro-inflammation; Sodium alginate

Mesh:

Substances:

Year:  2016        PMID: 27234497     DOI: 10.1016/j.ijbiomac.2016.05.078

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  6 in total

1.  Fucoidan Modulated Oxidative Stress and Caspase-3 mRNA Expression Induced by Sulfoxaflor in the Brain of Mice.

Authors:  Petek Piner Benli; Merve Kaya; Cagil Coskun
Journal:  Neurotox Res       Date:  2021-09-27       Impact factor: 3.911

2.  Oligosaccharide nanomedicine of alginate sodium improves therapeutic results of posterior lumbar interbody fusion with cages for degenerative lumbar disease in osteoporosis patients by downregulating serum miR-155.

Authors:  Yang Qu; Zhengming Wang; Haohan Zhou; Mingyang Kang; Rongpeng Dong; Jianwu Zhao
Journal:  Int J Nanomedicine       Date:  2017-11-24

3.  Low molecular weight fucoidan inhibits hepatocarcinogenesis and nonalcoholic fatty liver disease in zebrafish via ASGR/STAT3/HNF4A signaling.

Authors:  Szu-Yuan Wu; Wan-Yu Yang; Chun-Chia Cheng; Kuan-Hao Lin; Bonifasius Putera Sampurna; Suat-Ming Chan; Chiou-Hwa Yuh
Journal:  Clin Transl Med       Date:  2017-07-28

4.  Neuroprotective effect of sodium alginate against chromium-induced brain damage in rats.

Authors:  Eman M Saleh; Germine M Hamdy; Rasha E Hassan
Journal:  PLoS One       Date:  2022-04-14       Impact factor: 3.752

Review 5.  Anti-Inflammatory Mechanisms of Fucoidans to Treat Inflammatory Diseases: A Review.

Authors:  Kalu K Asanka Sanjeewa; Kalahe H I N M Herath; Hye-Won Yang; Cheol Soo Choi; You-Jin Jeon
Journal:  Mar Drugs       Date:  2021-11-28       Impact factor: 5.118

Review 6.  From Biomedical Applications of Alginate towards CVD Implications Linked to COVID-19.

Authors:  Angela Spoială; Cornelia-Ioana Ilie; Denisa Ficai; Anton Ficai; Ecaterina Andronescu
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.